Dr. De Censi Discusses the Results of the Phase III TAM-01 Trial in Breast Cancer

Andrea De Censi, MD
Published: Thursday, Feb 28, 2019



Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the results of the phase III TAM-01 trial in breast cancer.

This trial randomized 500 women with operated hormone sensitive breast ductal or lobular carcinoma in situ to receive either low-dose tamoxifen or placebo to assess the potential recurrence risk reduction. After a median follow-up of 5 years, results showed a 52% reduction in the risk of recurrence with low-dose tamoxifen compared with placebo, says De Censi, meeting the criteria for statistical significance.

Moreover, there were 14 (5.5%) events of disease recurrence in the tamoxifen arm versus 28 (11.3%) in the placebo arm (HR, 0.48; 95% CI, 0.26-0.92; P = .024). The number of events has been relatively low, he adds. More follow-up is needed to assess the benefit of low-dose tamoxifen in this patient population.
SELECTED
LANGUAGE


Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the results of the phase III TAM-01 trial in breast cancer.

This trial randomized 500 women with operated hormone sensitive breast ductal or lobular carcinoma in situ to receive either low-dose tamoxifen or placebo to assess the potential recurrence risk reduction. After a median follow-up of 5 years, results showed a 52% reduction in the risk of recurrence with low-dose tamoxifen compared with placebo, says De Censi, meeting the criteria for statistical significance.

Moreover, there were 14 (5.5%) events of disease recurrence in the tamoxifen arm versus 28 (11.3%) in the placebo arm (HR, 0.48; 95% CI, 0.26-0.92; P = .024). The number of events has been relatively low, he adds. More follow-up is needed to assess the benefit of low-dose tamoxifen in this patient population.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication
x